Form 10-Q aTYR PHARMA INC For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- US stock futures fall as fading Iran peace prospects drive up oil, yields
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
aTyr Pharma (LIFE) Trims Q3 Loss
November 11, 2015 7:38 AM ESTaTyr Pharma (NASDAQ: LIFE) reported Q3 EPS of ($0.48), versus ($8.02) reported last year.
For earnings history and earnings-related data on aTyr Pharma (LIFE) click here.
... MoreaTyr Pharma (LIFE) Selects iMod.Fc Molecule as IND Candidate
November 11, 2015 7:37 AM ESTaTyr Pharma (NASDAQ: LIFE) announced that it has selected an Investigational New Drug (IND) Candidate based on an immuno-modulatory and fibro-modulating Physiocrine domain fused to an Fc region of a human antibody, iMod.Fc. The selected iMod.Fc molecule is intended to address patients with severe pulmonary diseases with an immune and fibrotic component.
"The molecule developed in our iMod.Fc discovery program represents a major breakthrough as the first engineered Physiocrine with advantageous pharmaceutical properties... More
